Regulation of overall proteoglycan structure can arise from alteration in the expression of individual proteoglycan core proteins that will alter the mix of proteoglycans. In addition, alterations in the structure of individual proteoglycans can arise from a change in the length of the glycosaminoglycan (GAG) chains covalently attached to the proteoglycan core protein, alterations in the extent and position of the sulfate group(s) on the GAG chains, and an alteration of the carbohydrate structure being the sterioisomeric nature of the uronic acid ring (epimerization). These changes in matrix structure and composition have an important impact on the propensity of the matrix to bind and retain atherogenic lipoproteins as an early and potentially initiating step in the process that leads to the formation of life-threatening atherosclerotic plaques.
Very significant data are emerging to indicate that the structure of the ECM of blood vessels, particularly proteoglycans, can be modulated therapeutically to prevent vascular disease [7] . Modifying the ionic charges by altering the amino acids in the apoB100 molecule on LDL in a murine transgenic model, which prevents the binding of LDL to proteoglycans, greatly attenuates the development of atherosclerosis [8] . These data strongly support the contention above that the trapping of LDL in the vessel wall is an initiating step in atherosclerosis. Expert commentary on this work suggested that therapies that directly target the vessel wall were needed to prevent this form of vascular disease [9] . At present, the major approach to prevent this process is the blunt approach of lowering blood cholesterol levels by dietary changes or therapeutically with (cholestyramine) resins or HMG CoA reductase inhibitors ("statins"). Clinical trials adopting this approach always show an element of "resistant" or "residual" disease. The potential to discover and develop agents that target the vessel wall by altering the properties of proteoglycans to make them "less sticky" for LDL provides an opportunity to reduce or eliminate the resistant component of disease. Our recent study on the direct vascular effects of fenofibrate, a lipidlowering agent used for the treatment of hypertriglyceridemia in patients with and without Type 2 diabetes, shows that this therapeutic agent has antiatherogenic effects in vitro that lead to reduced proteoglycan-LDL binding [10] .
Atherogenic factors controlling GAG elongation in vSMCs leading to increased binding to LDL include transforming growth factor (TGF)-β1 [11] , angiotensin II [12, 13] , oxidized LDL [14] , free fatty acids [15] , and platelet-derived growth factor (PDGF) [16] (Table 1) . There are only a few reports on the pharmacological regulation of vSMC proteoglycan synthesis ( Table 2) . Treatment of vSMCs with troglitazone, a nonclinically used oral hypoglycaemic agent, and the clinically used rosiglitazone, which are both peroxisome proliferating activated receptor (PPAR)-γ ligands, leads to a reduction in GAG length on the proteoglycan, versican that is associated with reduced affinity for LDL [17] . Intriguingly, older hypoglycaemic agents, the biguanides and sulfonylureas, do not reduce vascular proteoglycan-lipid binding in vitro [18] . Tesaglitazar, a PPAR-α/γ ligand, reduces vSMC proteoglycans stimulated by albumin-bound linoleate [19] . The treatment of vSMCs with the antihypertensive calcium antagonists, amlodipine and nifedipine, produce proteoglycans with low ionic charge and this is associated with reduced binding to LDL [20] . Statins are an exception to the rule in that vSMCs treated with statins result in the secretion of proteoglycans with elongated GAG chains; however, these proteoglycans show reduced binding to LDL [21] . A likely mechanism for reduced LDL binding of GAGs from vSMCs treated with statins is reduced sulfation of GAGs; however, an investigation of the sulfation of the GAG from vSMCs treated with statins was not carried out [21] . A nontraditional therapeutic agent, glucosamine is a "natural" dietary supplement used to alleviate arthritis pain. Exogenous glucosamine can be modified metabolically by the hexosamine pathway and incorporated into GAG chains as N-acetylgalactosamine. Although one might expect supplement addition to increase GAG synthesis, treatment of vSMCs with exogenous glucosamine results in the production of proteoglycans with shorter GAG chains, but which have reduced affinity for LDL [22] . Our most recent study focused on the role of fenofibrate in regulating the synthesis and structure of proteoglycans synthesized by vSMCs. Human vSMCs were treated with fenofibrate and metabolically labeled with [
35 S]-sulfate in the presence and absence of atherogenic growth factors, TGF-β and PDGF. Secreted proteoglycans were assessed for [
35 S]-sulfate incorporation into proteoglycans by the CPC precipitation method, hydrodynamic size-by-size exclusion chromatography, and binding to LDL by the gel mobility shift assay. Fenofibrate treatment reduced [
35 S]-sulfate incorporation into proteoglycans under both TGF-β-and PDGF-stimulated conditions and the changes in sulfate incorporation were associated with a reduction in GAG length and reduced binding to LDL. Another agent in this class, gemfibrozil, also reduces GAG length [23] leading to reduced binding to LDL (Fig. 1) . We concluded that fenofibrate modifies the structure of vascular proteoglycans by reducing the length of the GAG chains and modifying GAG composition resulting in reduced binding to human LDL, a mechanism that may lead to a reduction in atherosclerosis and cardiovascular disease in high-risk subjects treated with fenofibrate (Fig. 2) .
Our study showed that fenofibrate has direct vascular actions that may complement the metabolic actions of fibrates in reducing cardiovascular disease. It remains to be resolved whether or not PPAR-α, the nuclear receptor target of this agent, is involved in regulating proteoglycan structure. The current results imply that fenofibrate, which is currently used to treat lipid abnormalities, may have an added benefit by directly acting on the vasculature. Our study would predict a favorable outcome for the Fenofibrate Intervention and Event Lowering in Diabetes ("FIELD") trial which is a long-term trial involving 12,000 people with Type 2 diabetes given micronized fenofibrate 200 mg/day or placebo [24] . This trial will determine whether or not fenofibrate has beneficial effects on the macrovascular complications of diabetes and will advance the "response to retention" hypothesis as a rational model of atherogenesis for developing therapies based on targeting the vessel wall. The more exciting possibility is that the pleiotropic actions identified for fenofibrate can be incorporated into a much more potent agent that specifically targets proteoglycan synthesis in the vessel wall as a primary action and current studies in our laboratory are focused on this area. ]-met/cys in the presence and absence of gemfibrozil (100 μmol/l) with (A) TGF-β1 (2 ng/ml) or (B) PDGF (50 ng/ml) with insulin (1 μM). Secreted proteoglycans from vSMCs were isolated and equal counts (1500 cpm) were mixed with increasing concentrations of LDL and separated by electrophoresis, on agarose gels. The percent of proteoglycans bound was plotted against the LDL concentration to generate binding curves. Open squares, TGF-β1-treated cells; closed squares, vSMCs treated with gemfibrozil (100 μmol/l) and TGF-β1; open triangles, PDGF-treated cells; closed circles, gemfibrozil (100 μmol/l) and PDGF/insulin. Each point (n = 2-4) represents the mean ± SEM from 1-2 experiments performed in duplicate and was analyzed using a using a paired t-test (*p < 0.05, **p < 0.01). FIGURE 2. Therapeutic modulation of CS/DS proteoglycan biochemical size and sulfation can reduce LDL binding and prevent atherosclerosis. The CS/DS proteoglycan biglycan consists of a core protein (orange), two GAG chains (red vertical extensions), which are sulfated (blue horizontal lines). Atherogenic growth factors such as PDGF and TGF-β1 stimulate SMCs to synthesize proteoglycans, which have longer GAG chains and altered sulfation pattern leading to higher affinity and higher-capacity binding of CS/DS proteoglycans to LDL particles (red). Therapeutic agents may reduce either/or the GAG length and the sulfation pattern of GAG chains leading to reduced binding of CS/DS proteoglycans to LDL.
